Scynexis Stock Price, News & Analysis

SCYNEXIS, Inc. announced presentations of interim data from its Phase 3 FURI study at IDWeek 2021, focusing on ibrexafungerp for treating refractory fungal infections. The study includes 74 patients, highlighting outcomes for infections caused by Candida, especially drug-resistant strains. This is significant as invasive fungal infections are challenging to treat due to rising antifungal resistance. The company aims to make ibrexafungerp available to patients globally, following its FDA approval for BREXAFEMME in June 2021.

SCYNEXIS has launched BREXAFEMME® (ibrexafungerp tablets), the first oral non-azole treatment approved by the FDA for vulvovaginal candidiasis (VVC), a common vaginal yeast infection. This innovative antifungal, effective against azole-resistant strains, is available in pharmacies nationwide. BREXAFEMME is a two-day regimen designed to kill the fungi rather than just inhibit growth. The drug has received Qualified Infectious Disease Product status and has 10 years of market exclusivity. With a favorable safety profile and patent protection until at least 2035, SCYNEXIS aims to expand its antifungal franchise.

SCYNEXIS has announced that its partner, Hansoh Pharma, has filed an IND application for a Phase 3 study of ibrexafungerp in China, targeting vulvovaginal candidiasis. This follows an exclusive licensing agreement between the companies to develop and commercialize ibrexafungerp in the region. Ibrexafungerp is the first new antifungal drug approved by the FDA in over two decades, emphasizing its potential in combating drug-resistant infections. The collaboration aims to leverage Hansoh's capabilities to enhance treatment accessibility for patients in China.

SCYNEXIS, a biotechnology company focused on innovative treatments for drug-resistant infections, will participate in two upcoming virtual investor conferences in September 2021. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, featuring an on-demand presentation and one-on-one meetings, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, with a live presentation. More information and archived webcasts will be available on their website for 30 days post-event.

SCYNEXIS announced financial results for Q2 2021, showcasing a strong cash position of $112.4 million. The company reported a net income of $1.7 million, reversing a loss of $6.4 million from the previous year. BREXAFEMME, the first FDA-approved antifungal in over 20 years, launched in August 2021, with positive payer engagement. Clinical advancements include completing enrollment in the Phase 3 CANDLE study and ongoing Phase 1 trials for a liposomal IV formulation. The company expects to sustain operations into 2023 driven by anticipated sales of BREXAFEMME.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced the granting of stock options to five new employees, allowing them to purchase a total of 24,500 shares at an exercise price of $6.97 per share, the closing price on July 30, 2021. This grant serves as an incentive for accepting job offers and will vest over a four-year period. SCYNEXIS focuses on developing innovative antifungal treatments, including the recently FDA-approved BREXAFEMME (ibrexafungerp), targeting drug-resistant infections in both community and hospital settings.

SCYNEXIS, Inc. (NASDAQ: SCYX) presented data from two Phase 3 studies (VANISH-303 and VANISH-306) on oral ibrexafungerp for treating vulvovaginal candidiasis (VVC). The studies targeted patients with severe yeast infections and showed ibrexafungerp's efficacy and safety. Results indicated a Clinical Cure Rate of 56.9% for ibrexafungerp compared to 35.7% for placebo (p=0.001). The FDA approved BREXAFEMME® for the treatment of VVC, marking a significant milestone as the first new class of antifungal agent in over 20 years. Further studies are ongoing for recurrent VVC prevention.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced promising presentations for ibrexafungerp at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data highlight ibrexafungerp's effectiveness against challenging fungal infections, including drug-resistant Candida auris. In vitro studies showed broad activity of ibrexafungerp against 967 clinical isolates in Denmark. From the FURI study, 70% of patients with refractory fungal diseases demonstrated clinical improvement, while 80% of patients in the CARES study achieved a complete response for Candida auris infections.

SCYNEXIS, Inc. (NASDAQ: SCYX) has announced that CFO Eric Francois will present at Ladenburg Thalmann’s virtual Healthcare Conference on July 14, 2021, from 11:00 to 11:25 AM ET. This presentation will highlight the company’s innovative medicines aimed at combating drug-resistant infections, particularly their lead asset, ibrexafungerp. The company recently received FDA approval for BREXAFEMME (ibrexafungerp tablets) on June 1, 2021. The conference webcast will be accessible for three months on the SCYNEXIS website.